Format

Send to

Choose Destination
Clin Microbiol Rev. 2003 Jan;16(1):114-28.

Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy.

Author information

1
GlaxoSmithKline Consumer Healthcare, Weybridge, Surrey KT15 0DE, United Kingdom. teresa.h.bacon@gsk.com

Abstract

Acyclovir, penciclovir, and their prodrugs have been widely used during the past two decades for the treatment of herpesvirus infections. In spite of the distribution of over 2.3 x 10(6) kg of these nucleoside analogues, the prevalence of acyclovir resistance in herpes simplex virus isolates from immunocompetent hosts has remained stable at approximately 0.3%. In immuncompromised patients, in whom the risk for developing resistance is much greater, the prevalence of resistant virus has also remained stable but at a higher level, typically 4 to 7%. These observations are examined in the light of characteristics of the virus, the drugs, and host factors.

PMID:
12525428
PMCID:
PMC145299
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center